Ascendis Pharma price target raised to $152 from $142 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Ascendis Pharma to $152 from $142 and keeps an Overweight rating on the shares following the Q1 results. Skytrofa had a strong beat in Q1, and the company also guided to FY sales of EUR150M-EUR160M for U.S. only for the first time, the analyst tells investors in a research note. The firm views this as a big positive for the company, but says deficiency issues remain unknown for TransCon PTH.